[The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma]
- PMID: 16620672
[The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma]
Abstract
Objective: To investigate the expression of clusterin protein in bladder transitional cell carcinoma (BTCC) and it's association with tumor cell proliferation and apoptosis.
Methods: A tissue microarray (TMA) containing 87 informative cases of BTCCs was constructed firstly. The methods of immunohistochemistry and terminal deoxynucleotidyl transferase-mediated nick end-labeling were then used to examine the expression of clusterin and Ki-67 protein and the status of cell apoptosis in BTCC, respectively, and the correlations between different markers and the clusterin expression associated with patients' clinico-pathological features were evaluated.
Results: In TMA of 87 BTCCs, 37 (43%) cases were observed overexpression of clusterin. A significant association of clusterin expression with BTCC's pathological grade, as well as with tumors clinical stage was observed (P < 0.01), where the frequency of overexpression of clusterin in poor differentiated BTCCs (G(3), 71%) and tumors in more advanced stage (T(2-4), 62%) was significantly higher than that in well differentiated BTCCs (G(1-2), 29%) and tumors in early stage (T(a-1), 28%). In addition, a significant correlation between clusterin expression and tumors apoptotic index (AI) was evaluated (P < 0.01), in which 57% of BTCCs with overexpression of clusterin were observed a lower AI, while 72% of tumors with normal expression of this protein showed a higher AI, but no correlation between clusterin and Ki-67 expression.
Conclusions: The overexpression of clusterin is associated positively with BTCC's malignant clinical phenotypes including tumor's differentiation and invasive depth, and it is correlated inversely with AI of tumor cells.
Similar articles
-
[The clinical significance of expression and amplification of FGF3 in bladder transitional cell carcinoma].Zhonghua Yi Xue Za Zhi. 2006 Sep 26;86(36):2556-9. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17198565 Chinese.
-
[The clinico-pathological significance of protein expression of PAK1 in bladder transitional cell carcinoma].Zhonghua Yi Xue Za Zhi. 2007 Oct 16;87(38):2710-3. Zhonghua Yi Xue Za Zhi. 2007. PMID: 18167251 Chinese.
-
[Correlation of clusterin expression to prognosis of bladder carcinoma].Ai Zheng. 2005 Jun;24(6):743-7. Ai Zheng. 2005. PMID: 15946493 Chinese.
-
Molecular pathology of low malignant bladder transitional cell carcinoma: a current perspective.Histol Histopathol. 2005 Jan;20(1):147-53. doi: 10.14670/HH-20.147. Histol Histopathol. 2005. PMID: 15578434 Review.
-
Molecular pathways in bladder cancer: part 2.BJU Int. 2005 Mar;95(4):491-6. doi: 10.1111/j.1464-410X.2005.05326.x. BJU Int. 2005. PMID: 15705066 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical